anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ovarian-type (ie, Mullerian) epithelial tumors occurring in the testicular and paratesticular regions are exceptionally rare, with only a handful reported worldwide. Serous tumors are the most frequently encountered subtype among these rare tumors. The pathogenesis of these tumors within the testicular and paratesticular regions remains a subject of intrigue and debate, with various hypotheses attempting to explain their presence in the paratestis region, where most tumors occur. However, our understanding of the pathogenesis of intratesticular tumors is limited. To date, 11 known examples of intratesticular serous Mullerian tumors have been reported globally. In this report, we present an extraordinary tumor, an intratesticular Mullerian serous borderline tumor with foci of microinvasion, in a 38-year-old male patient. This tumor exhibits histological features similar to their ovarian counterparts and is confirmed through an immunohistochemical panel. Our report underscores the extreme rarity of these tumors, emphasizes the importance of heightened awareness among clinicians and pathologists, and provides valuable insights into their complex development and histogenesis. This contribution aims to enhance diagnostic precision and optimize therapeutic strategies for similar tumors.
A photoelectric spun fiber membrane with an anti-tumor function and a preparation method and application thereof belong to the field of medical instruments. The photothermal and electric spinning fiber membrane with the anti-tumor function is formed by uniformly distributing Prussian blue nano-particles in alcohol-soluble protein fibers. The preparation method comprises the following steps: mixing Prussian blue nano-particles with an ethanol water solution to prepare a suspension; and adding alcohol soluble protein powder into the suspension, performing electrostatic spinning on the obtained mixed solution, and performing curing and crosslinking to obtain the photothermal and electric spinning fiber membrane with the anti-tumor function. The application of the medicine is used for treating tumor after operation, the medicine is pasted on a wound area after the operation of the tumor, high heat is generated under the irradiation of near infrared laser, residual tumor cells are killed, and the tumor recurrence is prevented. Then the fibrous membrane is similar to the porous structure of the extracellular matrix and the amino acid gradually degraded and released by the fibrous membrane promotes the proliferation of surrounding normal cells, accelerates the healing of tissues and restores the normal function. It has improved photothermal, laminating and healing effects.
The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a polycationic complexing agent which is complexed with a therapeutic, prophylactic or diagnostic agent or any combination thereof having a charge capable of complexing with the polycationic complexing agent upon association with the bioactive agent. The particles can further comprise a pharmaceutically acceptable carrier. The amount of polycationic complexing agent present in the particles is an amount sufficient to sustain the release of diagnostic, therapeutic or prophylactic agent from the particles. For example, the amount of complexing agent present can be at about 5% weight/weight (w/w) or more of the total weight of the complexing agent and therapeutic, diagnostic or prophylactic agent. Release of the agent from the administered particles occurs in a sustained fashion.
BACKGROUND: Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-negative MPNs) are linked with various complications, notably ischemic stroke. The study aims to identify risk factors for ischemic stroke in Ph-negative MPNs patients.
METHODS: Patients were categorized into two groups based on whether they had experienced ischemic stroke. Subsequently, an analysis of demographics, biochemical makers, and genetic mutations (JAK2V617F and CALR mutations), was conducted to identify potential associations with an elevated risk of ischemic stroke in individuals with Ph-negative MPNs.
RESULTS: A total of 185 patients diagnosed with Ph-negative MPNs participated in the study, including 82 with essential thrombocythemia (ET), 78 with polycythemia vera (PV), and 25 with primary myelofibrosis (PMF). Among these, 57 patients (30.8 %) had a history of ischemic stroke. Independent risk factors associated with ischemic stroke in Ph-negative MPNs patients included hypertension (OR = 5.076) and smoking (OR = 5.426). Among ET patients, smoking (OR = 4.114) and an elevated percentage of neutrophils (OR = 1.080) were both positively correlated with ischemic stroke incidence. For PV patients, hypertension (OR = 4.647), smoking (OR = 6.065), and an increased percentage of lymphocytes (OR = 1.039) were independently associated with ischemic stroke. Regardless of the presence of the JAK2V617F mutation, hypertension was the sole positively and independently associated risk factor for ischemic stroke. The odds ratios for patients with the JAK2V617F mutation was 3.103, while for those without the mutation, it was 11.25.
CONCLUSIONS: Hypertension was a more substantial factor associated with an increased incidence of ischemic stroke in Ph-negative MPNs patients.
After graduation, CME is one of the important step to improve both the graduate's competencies and the quality of healthcare services. Throughout the professional career paths, nurse anesthetists in different career stages have different level of competency and expectations. Retention of knowledge and skills are much different between the new graduate nurses and mid to late career nurse. Feasible training program by using interactive teaching methods can improve the learner's satisfaction. There are just only few anesthesia education courses for nurse anesthetists in each year. These may be not enough in order to maintain either knowledge or essential skills needed in anesthesia real life practice. The primary objective of this is to determine that which kinds of knowledge and skills in anesthesia that the nurse anesthetists in our institution lack off. The secondary objective is the correlation between anesthesia non-technical skills (ANTS) and years of experience among nurse anesthetists. The results of this study will be useful information for creating additional anesthesia training course for this graduate group. Furthermore, Improving the anesthesia standard of care in the near future.

In this study, the investigator team designs to use self-evaluating form as a tool for any competencies evaluation. The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used. After ethical committee approval, the subject group will be invited by the investigator team by using participant information form. In case of the participants have willing to enroll in this study. The consent form must be signed and then the participant could download the self-evaluating form (google form, no personal identity record) via QR code. After data collection completion, the statistical analysis will be done by using R program. The statistically significance is set as p\< 0.05.
To assess the clinical effect of the esomeprazole absorption after Roux-en-Y gastric bypass, we intend to measure the serum concentration after administration as intact capsules or open in solution and correlate it with the pH in the gastric pouch, measured with the wireless BRAVOTM capsule pH measurement system. The feasibility and safety of the wireless pH monitoring system has been shown before.

The patients who met all the inclusion criteria undergo a routine upper endoscopy one year after RYGB. At the end of the endoscopy, the wireless BRAVO™ - pH monitoring device is placed and the participant is discharged with ongoing pH monitoring. The next day, the participant is randomized to either receive Esomeprazol MUT Sandoz® tablet 40mg or Esomeprazol MUT Sandoz® 40mg in solution. Serum concentration of Esomeprazol is measured at 0, 60 and 120 minutes and the patient is discharged after. After 48 hours of pH monitoring, the patient returns the BRAVO™ - recorder, adverse events are assessed and the study is terminated.
A dose-dependent prolongation of the QT interval was observed within 10 minutes of droperidol administration in a study of 40 patients without known cardiac disease who underwent extracranial head and neck surgery. Significant QT prolongation was observed at all three dose levels evaluated, with 0.1, 0.175, and 0.25 mg/kg associated with prolongation of median QTc by 37, 44, and 59 msec, respectively.

Cases of QT prolongation and serious arrhythmias (e.g. torsade de pointes, ventricular arrythmias, cardiac arrest, and death) have been observed during post-marketing treatment with droperidol. Some cases have occurred in patients with no known risk factors and at doses at or below recommended doses. There has been at least one case of nonfatal torsade de pointes confirmed by rechallenge.

Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present. If there is a prolonged QT interval, droperidol should NOT be administered. For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hours after completing treatment to monitor for arrhythmias.

FLUIDS AND OTHER COUNTERMEASURES TO MANAGE HYPOTENSION SHOULD BE READILY AVAILABLE.

As with other CNS depressant drugs, patients who have received droperidol should have appropriate surveillance.

It is recommended that opioids, when required, initially be used in reduced doses.

As with other neuroleptic agents, very rare reports of neuroleptic malignant syndrome (altered consciousness, muscle rigidity and autonomic instability) have occurred in patients who have received droperidol. Since it may be difficult to distinguish neuroleptic malignant syndrome from malignant hyperpyrexia in the perioperative period, prompt treatment with dantrolene should be considered if increases in temperature, heart rate or carbon dioxide production occur.
PURPOSE:To obtain the subject agent effective for remarkably preventing the generation and growth of hair and having high safety by using extracted liquid of cultured cell P19 or its cultivation supernatant as an active component. CONSTITUTION:P19 cell which is a mouse fetus carcinoma cell is disintegrated by arbitrary method and the extract or cultivation supernatant is used as an active component to obtain the objective trichogenous and hair-tonic agent. Although P19 cell is a carcinoma cell, it can be differentiated to normal cell by various treatments and an individual originated from the cell can be obtained by introducing the cell into an early embryo of mouse. It can be used in any form applicable to the scalp (e.g. liquid, aerosol, milky lotion or ointment) or injectable by subcutaneous injection (e.g. liquid or suspension).
Acute febrile neutrophilic dermatosis, or Sweet syndrome, has been described in 1964 and is now considered as a prototypical condition of the group of the neutrophilic dermatoses. Since this time, many clinical conditions have been included in this group and a clinical-pathological classification in 3 subgroups has been proposed. Neutrophilic infiltrates can localize in all internal organs. This defines the neutrophilic disease, which induces difficult diagnostic and therapeutic problems. Autoinflammation is the main pathophysiological mechanism of the neutrophilic dermatoses. There is a special link between myeloid malignancies (leukemia and myelodysplasia) and the neutrophilic dermatoses.
BACKGROUND/AIM: Hypothyroidism induced by roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, was recently reported; however, information regarding roxadustat-associated hypothyroidism is still lacking. We explored the risk and time to onset of hypothyroidism associated with HIF-PH inhibitors using the Japanese Adverse Drug Event Report (JADER), a pharmacovigilance database.
PATIENTS AND METHODS: The participants of this study were registered in the JADER database between April 2004 and March 2023. The association between HIF-PH inhibitors and hypothyroidism was evaluated using the reporting odds ratio (ROR) and information component (IC). We also calculated the period from the start of drug administration to the onset of hypothyroidism and determined the onset pattern using Weibull distribution.
RESULTS: Roxadustat had positive signals for hypothyroidism among the HIF-PH inhibitors based on the ROR [31.03, 95% confidence interval (CI)=27.81-34.62] and IC (4.51, 95%CI=4.36-4.67) values, and a strong relationship was confirmed. In addition, the median time to roxadustat-associated hypothyroidism onset was 92 days, and over 50% of cases occurred within 100 days of starting treatment. Furthermore, the onset pattern was an early failure type.
CONCLUSION: There is a possible association between roxadustat and hypothyroidism. Therefore, enhanced thyroid function testing within 100 days of treatment initiation may help detect roxadustat-associated hypothyroidism. However, further research is required to confirm these findings, considering study limitations using databases of spontaneous adverse event reports.
Five study periods (Screening, Baseline, Pre-gene Therapy Infusion, Gene Therapy Infusion, and Post-gene Therapy Infusion Follow-up) comprised the study. During the Screening Period (approximately 60 days), written informed consent was obtained and the subject completed other Screening procedures to confirm study eligibility. Once study eligibility was confirmed, subjects entered the Baseline Period (up to 7 days) during which time assessments were performed to establish Pre-gene Therapy Infusion baseline. Once baseline assessments were completed, the subject entered the Pre-gene Therapy Infusion Period (approximately 8 to 10 weeks) during which time mobilization, apheresis, AVR-RD-02 investigational product preparation and testing for release, busulfan conditioning regimen administration took place. Enzyme replacement therapy was discontinued at least 2 weeks before the scheduled Gene Therapy Infusion Day. Following completion of the Pre-gene Therapy Infusion Period, the subject entered the Gene Therapy Infusion Period (1 day) during which AVR-RD-02 infusion took place. After AVR-RD-02 Gene Therapy Infusion, the subject entered the Post-gene Therapy Infusion Follow-up Period (approximately 52 weeks) during which time periodic safety and efficacy assessments were performed to assess measures of safety, engraftment, and clinical response following AV-RD-02 infusion.

In August 2023, the study was terminated early by the Sponsor, which was not based on any safety or medical reasons and therefore, one subject did not complete the study (i.e., Week 52). Subsequently, in August 2023, the sponsor's long-term follow-up study (AVRO-RD-02-LTF01), was also terminated early for the same reason as the AVRO-RD-02-201 study, and therefore, no subjects completed the 15-year long-term follow-up study.
BACKGROUND: Avoidant/restrictive food intake disorder (ARFID) prevalence in children with gastroparesis (Gp) and/or functional dyspepsia (FD) is unknown. We aimed to identify ARFID prevalence and trajectory over 2 months in children with Gp, FD, and healthy children (HC) using two screening questionnaires. We also explored the frequency of a positive ARFID screen between those with/without delayed gastric emptying or abnormal fundic accommodation.
METHODS: In this prospective longitudinal study conducted at an urban tertiary care hospital, patients ages 10-17 years with Gp or FD and age- and gender-matched HC completed two validated ARFID screening tools at baseline and 2-month follow-up: the Nine Item ARFID Screen (NIAS) and the Pica, ARFID, and Rumination Disorder Interview-ARFID Questionnaire (PARDI-AR-Q). Gastric retention and fundic accommodation (for Gp and FD) were determined from gastric emptying scintigraphy.
KEY RESULTS: At baseline, the proportion of children screening positive for ARFID on the NIAS versus PARDI-AR-Q was Gp: 48.5% versus 63.6%, FD: 66.7% versus 65.2%, HC: 15.3% versus 9.7%, respectively; p < 0.0001 across groups. Of children who screened positive at baseline and participated in the follow-up, 71.9% and 53.3% were positive 2 months later (NIAS versus PARDI-AR-Q, respectively). A positive ARFID screen in Gp or FD was not related to the presence/absence of delayed gastric retention or abnormal fundic accommodation.
CONCLUSIONS & INFERENCES: ARFID detected from screening questionnaires is highly prevalent among children with Gp and FD and persists for at least 2 months in a substantial proportion of children. Children with these disorders should be screened for ARFID.
I read the study by Zhao et al with great interest. Although the study design was quite complicated, it was successful in raising awareness of science and relevant researchers. Thirty patients with liver cirrhosis and portal hypertension secondary to chronic hepatitis B were included in the study. They were treated for variceal bleeding and underwent trans-jugular intrahepatic portosystemic shunt to prevent the recurrence of variceal bleeding and to reduce portal pressure. The authors evaluated the effects of changes in gut microbiota (GM) on hepatic encephalopathy secondary to portocaval bypass. The GM is greatly affected by local and general factors, including herbal and medical drugs, a person's dietary characteristics (carnivorous, vegan, vegetarian), supplementary foods, drinking water sources, and living in a city center or town. Therefore, I congratulate Zhao et al for their concise and comprehensive study on a multifactorial subject.
FIELD: oncology.SUBSTANCE: cytoreduction is performed by performing a lower midline laparotomy with an extension of the incision above the navel. The great omentum is removed, the uterus with the appendages is extirpated, all resectable metastases are removed. Then the vaginal stump is sutured, peritonization is performed. After that, hemostasis is performed in the tumor bed by coagulation and ligation of bleeding vessels. Then, a video endoscopic stage is carried out, for which two trocars are installed: one is installed in the epigastric region, and the other in the hypogastric region. The laparotomic wound is hermetically sutured without installing drains. After sealing the abdominal cavity, carbon dioxide is supplied through the trocar into the abdominal cavity, and a carboxyperitoneum is formed with an intraperional pressure of 12-15 mm Hg. In this case, a laparoscope is introduced through the trocar in the epigastric region; a nozzle is introduced into the hypogastrium through the trocar, which is connected to the injector. By means of an injector, aerosol is sprayed with solutions of cytostatics: cisplatin 10 mg/m2and doxorubicin 2.1 mg/m2. Aerosol intra-abdominal chemotherapy is carried out with exposure of a cytostatic aerosol for 30 minutes at an intra-abdominal pressure of 12-16 mm Hg. Upon completion of the exposure, visual control is carried out, if necessary, coagulation hemostasis, carboxyperitoneum is eliminated by means of a vacuum aspirator. Trocars are removed, trocar holes are sutured tightly.EFFECT: method allows achieving tumor regression in ovarian cancer with peritoneal carcinomatosis, without increasing cytostatic toxicity, due to the simultaneous use of surgical cytoreduction and intra-abdominal aerosol chemotherapy under pressure according to the original scheme.1 cl, 2 ex
Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
No intervention will be made to the control group, and the routine care practice of the clinic will be applied. "Ramsey Sedation Scale", "Patient Identification Form", "Patient Follow-up Form", "Behavioral Pain Scale" to determine pain level, "Behavioral Pain Scale" to determine the level of anxiety, at the first interview 48 hours after hospitalization in intubated patients hospitalized in the 3rd Stage Intensive Care Unit. Data will be collected by face-to-face interview method, "Face Anxiety Scale". Hemodynamic parameters will be recorded. Patient Follow-up Form, Behavioral Pain Scale and Face Anxiety Scale will be filled again during and after tracheal aspiration (30 minutes later).
OBJECTIVE: To evaluate an intervention that combines high intensity aerobic exercise with strength (AAAD) on general cognitive performance of patients affected by mild Alzheimer's disease (AD). DESIGN: Randomized clinical trial in two parallel groups: SCOPE: 2 health center of Basque Health Service , in coordination with its reference neurology services. PARTICIPANTS: 80 patients with mild AD.

INTERVENTION: Both groups receiving standard drug treatment. The intervention group also receive a supervised EEAA program, while the control group receive a similar intervention at low intensity. Patients are followed up over 1 year. Three blind measurements are made repeatedly : baseline, at 6 and 12 months. MEASUREMENTS: The primary outcome measure is change in cognitive performance that is measured in a blinded way with the cognitive section of the ADAS scale (Alzheimer's Disease Assessment Scale) at 0, 6 and 12.Secondary Outcomes: Global cognitive performance (Neuropsychological battery TBR-B),neuropsychiatric symptoms (NPI), ADL (Blessed),functional capacity (Test of 6-minute walk), cardiorespiratory Test, muscular strength (hand dynamometer and trunk); PREDICTORS AND CONFOUNDING VARIABLES: baseline cognitive performance, previous physical activity, medication, age, sex, APOE, schooling and cognitive reserve. ANALYSIS: We compared the two groups in terms of observed mean changes from baseline in ADAS measurement and other variables, intention to treat, using longitudinal mixed effects models for repeated measures at 6 and 12 months.
PURPOSE: A composition containing NADH is provided to quickly recover muscle fatigue by NADH. CONSTITUTION: A pharmaceutical composition for recovering muscle fatigue contains NADH(nicotinamide adenine dinucleotide) as an active ingredient. The muscle is red muscle. The effective amount of NADH is 1-20 mM. The composition is used in the form of a tablet, pill, capsule, granule, powder, liquid, or injection solution. A health food composition for preventing muscle fatigue contains NADH as an active ingredient. The health food composition is a solid food, gel phase food or drink.